Chronic stress enhances progression of acute lymphoblastic leukemia via β-adrenergic signaling


ABSTRACT

Clinical studies suggest that stress-related biobehavioral factors can accelerate the progression of hematopoietic cancers such as acute lymphoblastic leukemia (ALL), but it is unclear whether such effects are causal or what biological pathways mediate such effects. Given the network of sympathetic nervous system (SNS) fibers that innervates the bone marrow to regulate normal (non-leukemic) hematopoietic progenitor cells, we tested the possibility that stress-induced SNS signaling might also affect ALL progression. In an orthotopic mouse model, Nalm-6 human pre-B ALL cells were transduced with the luciferase gene for longitudinal bioluminescent imaging and injected i.v. into male SCID mice for bone marrow engraftment. Two weeks of daily restraint stress significantly enhanced ALL tumor burden and dissemination in comparison to controls, and this effect was blocked by the β-adrenergic antagonist, propranolol. Although Nalm-6 ALL cells expressed mRNA for β1- and β2-adrenergic receptors, they showed no evidence of cAMP signaling in response to norepinephrine, and norepinephrine failed to enhance Nalm-6 proliferation in vitro. These results show that chronic stress can accelerate the progression of human pre-B ALL tumor load via a β-adrenergic signaling pathway that likely involves indirect regulation of ALL biology via alterations in the function of other host cell types such as immune cells or the bone marrow microenvironment.

1. Introduction

Clinical and epidemiological studies have shown that stress-related biobehavioral factors are associated with accelerated progression of several types of cancer, including solid epithelial tumors and hematopoietic tumors such as leukemia (Antoni et al., 2006; Chida et al., 2008). Most experimental research on the biological mechanisms of such effects has been performed in the context of solid epithelial tumors (Armaiz-Pena et al., 2009; Thaker and Sood, 2008), which involve different molecular pathways from those in hematopoietic cancers (Vogelstein and Kinzler, 2002). Among the hematopoietic cancers that have been examined in experimental animal models, most studies have focused on leukemia and have found contradictory effects of stress on survival.

Early studies of stress effects on leukemia in animal models focused on infection with murine viruses that induced leukemic disease specific to the species. One study found a protective effect of chronic shock avoidance stress on the incidence and survival of Rauscher virus-induced leukemia (Jensen, 1968; Rasmussen, 1969). Another study found that restraint stress delayed Friend virus-induced incidence of erythroleukemia but only in males (Gotoh et al., 1986). In contrast, a more recent series of studies involving experimental injection of a leukemic rat NK cell line found that an acute period of forced swim stress or adrenaline injection at the time of leukemia cell injection increased subsequent mortality rates via a β-adrenergic receptor-dependent mechanism (Avraham et al., 2006; Ben-Eliyahu et al., 1999; Inbar et al., 2011). The heterogeneity of results across separate reports may stem from differences in the leukemia model systems used (e.g., viral induction of leukemia or progression of already established NK leukemia), differences in the outcomes analyzed (e.g., tumor incidence or survival time), and/or the specific stress paradigms utilized (e.g., repeated shock, restraint, or acute swim stress).
As previous animal models of leukemia have used time to morbidity or mortality rate as their outcomes, it remains unclear whether animals died sooner because stress increased the total leukemia tumor burden or because stress increased vulnerability to the lethal downstream sequelae of leukemia tumor burden, which may include infection, hemorrhage, and asphyxia. Most human leukemias stem from a malignant myeloid or lymphoid progenitor cell that colonizes the bone marrow at the expense of normal progenitor cells, resulting in the failure of normal hematopoiesis and the onset of life-threatening lymphopenia, thrombocytopenia, and anemia (Sawyers et al., 1991). Accurately quantifying the total tumor burden of such “liquid tumors” has historically been difficult, because, like normal lymphocytes, leukemia cells originating in the bone marrow may circulate throughout the body and home to a variety of distant tissue sites, including lungs and the central nervous system. However, recent advances in bioluminescence-based imaging allow repeated longitudinal measurement of growing tumor burdens within individual hosts and have provided new insights into the biological pathways by which stress can affect the growth of solid epithelial tumors such as breast cancer (Sloan et al., 2010).

We sought to harness this bioluminescent approach in the present study to directly quantify the effects of stress on tumor burden and dissemination in an orthotopic mouse model of human leukemia. Human leukemias are broadly grouped into four types based on the kinetics of disease development and the malignant progenitor cell type. These include chronic myeloid leukemia, acute myeloid leukemia, acute lymphoblastic leukemia, and acute lymphoblastic leukemia (Leukemia & Lymphoma Society, 2010). Of the four types, acute lymphoblastic leukemia (ALL) is the most common type of cancer in young children, and pre-B cell ALL is the most prevalent specific form of leukemia in children and adolescents (Koleno et al., 2010; Pui et al., 2008; Pui, 2009). Thus, we utilized a well-established mouse xenograft model of pre-B ALL (Sipkins et al., 2005; Colmone et al., 2008) that recapitulates key features of human leukemia pathogenesis, including orthotopic bone marrow colonization, hematopoietic failure, systemic dissemination, and neurological-motor deficits. Given the well-described sympathethetic nervous system (SNS) innervation of the bone marrow and hematopoietic progenitor cell function (Katayama et al., 2006; Mendez-Ferrer et al., 2008), and the involvement of β-adrenergic mechanisms in the progression of other tumors (Glanser et al., 2010; Inbar et al., 2011; Melamed et al., 2005; Sloan et al., 2010; Thaker et al., 2006), we also examined the role of β-adrenergic signaling as a potential mediator of stress effects on pre-B ALL tumor burden and dissemination.

2. Methods

2.1. Animals

Male SCID mice (Charles River Laboratories), 6–8 weeks of age, were maintained under BSL2 barrier conditions and housed in an individually ventilated cage (IVC) rack in double filter disposable cages (Innovive, Inc.), in groups of 4–5 per cage, with corn cob bedding and ad libitum access to food and water on a 12:12 light/dark cycle at 22 °C. All experimental procedures were approved by the Institutional Animal Care and Use Committee of the University of California, Los Angeles.

2.2. In vivo model of acute lymphoblastic leukemia

Human Nalm-6 pre-B ALL cells were transduced with the FUHlucW lentiviral vector containing firefly luciferase under the control of the constitutively active ubiquitin-C promoter (Morizono et al., 2005) and cultured in RPMI-1640 with l-glutamine (Cellgro-Mediatech, Inc., #10-040-CV) supplemented with 10% FBS (Atlanta Biologicals, #S151550H), 100 IU penicilllin/ml, 100 μg streptomycin/ml (Cellgro-Mediatech, Inc., #30-002-CI), at 37 °C, 5% CO2. Cells (5 × 10⁴) were injected into the lateral tail vein for bone marrow engraftment as previously described (Sipkins et al., 2005). Tumor burden and dissemination of the cells were tracked in live mice by repeated noninvasive optical imaging of leukemia-specific luciferase activity using an IVIS Lumina II system coupled to a desktop computer running Living Image 4.0 software (Caliper Life Sciences). After anesthetization with 2% isoflurane and intravenous injection of 150 mg/kg luciferin, mice were photographed under bright-field illumination and images were overlaid with luminescence data gathered over the maximum exposure period without pixel saturation (0.5–300 s).

Flow cytometry was used to examine the proportion of human Nalm-6 ALL cells to normal mouse leukocytes in femoral bone marrow based on Nalm-6 cell expression of human CD10 (Ganjoo et al., 1996). Marrow was collected with cold phosphate buffered saline without calcium and magnesium (PBS) (Cellgro-Mediatech, Inc., #21-031-CV), supplemented with 1% FBS, and subjected to red blood cell lysis buffer (BD Biosciences, #555899). White blood cells were incubated with PE-conjugated antibodies against human CD10 (BD Biosciences, #555375), washed, and analyzed on a FACSAria II High-Speed Cell Sorter with FACSdiva software (BD Biosciences) for analysis of total live lymphocytes from gating based on forward- versus side-scatter profiles.

2.3. Chronic restraint stress

Mice were randomly assigned to home cage control conditions or 2 h per day restraint for 14 consecutive days commencing on the day after leukemia cell injection. Mice were restrained in a confined space that prevented them from moving freely but did not press on them (Thaker et al., 2006). This paradigm has been shown to induce chronic stress as shown by neuroendocrine activation (Thaker et al., 2006; Manni et al., 2008), weight loss (Smagin et al., 1999), and anxiety-like behaviors (Hermann et al., 1994). Four experiments were completed, with n = 4 or 5 mice per group (stress vs. control) for each experiment.

2.4. β-adrenergic receptor blockade

Propranolol hydrochloride (Sigma, #P8688) in PBS vehicle, or an equivalent volume of vehicle alone for placebo, was administered via Alzet osmotic mini-pumps (DURECT Corporation) implanted subcutaneously on the lateral dorsal side of the mouse near the scapula to deliver a dose of 2 mg/kg/d beginning 8 days before initiation of restraint stress. Three experiments with propranolol blockade were conducted and included the following groups: (1) stress + propranolol; (2) stress + placebo; (3) control + placebo. For each experiment, n = 4 or 5 mice per group. To test for an effect of propranolol alone, the last of the three experiments utilized a fourth group, (4) control + propranolol (n = 5).

2.5. β-adrenergic receptor gene expression

To assess the expression of mRNA for human β1-, β2-, and β3-adrenergic receptors in Nalm-6 ALL cells, total RNA from 3 × 10⁶ cells was extracted (Qiagen RNeasy Mini Kit, #74104) and cleared of contaminating DNA with on-column DNase...
digestion (Qiagen RNase-Free DNase Set, #79254). Resulting RNA was assayed by quantitative one-step RT-PCR (Qiagen Quantitect Probe RT-PCR, #204443) using a sequence-specific primer-probe set for each gene (Applied Biosystems TaqMan Gene Expression Assays; ADRB1, #HS02330048_s1; ADRB2, #HS00240532_s1; ADRB3, #HS00609046_m1). Two independent RT-PCR runs were completed using triplicate determinations for each gene on each run according to the manufacturer's specified protocol on a Bio-Rad iCycler Real-Time Detection System, with adrenergic receptor threshold cycle numbers normalized to values of β-actin mRNA amplified in parallel (ACTB, #Hs99999903_m1) and expressed relative to values from a no-template control.

2.6. β-adrenergic receptor signaling

To determine the functionality of β-adrenergic receptors on Nalm-6 ALL cells, intracellular cyclic adenosine monophosphate (cAMP) signaling was measured at 0, 5, and 15 min after stimulation with 10 μM norepinephrine (Sigma, #A9512), as previous studies indicate optimal leukocyte activation of cAMP flux by 2.7. In vitro proliferation

To determine whether norepinephrine increased intracellular cAMP levels, and experiments were conducted, and cAMP levels for each condition at each time point were assayed in duplicate by ELISA according to the manufacturer's instructions (R&D Systems, #KGE002B) on a colorimetric microplate reader (Molecular Devices).

2.7. In vitro proliferation

A potential direct effect of β-adrenergic signaling on Nalm-6 ALL proliferation was tested by treating cells in vitro with norepinephrine at 1 or 10 μM. Proliferation was assessed by hemocytometry at 2, 6, 12, 24, 48, 72, and 96 h after treatment. In each of three independent experiments, duplicate samples were prepared for each condition at each time point.

2.8. Statistical analysis

Data are presented as mean ± SE, and all statistical analyses were carried out using SAS version 9.2 (SAS Institute Inc.). All distributions were examined for outliers and non-normality, and log transformations were applied to normalize distributions where necessary. Mixed-effects linear models (SAS PROC MIXED) were used to analyze datasets pooled across experiments to assess the overall effect of chronic restraint stress on the longitudinal growth trajectory of ALL, to determine whether those effects were modified by pharmacologic intervention with propranolol, to determine whether norepinephrine increased intracellular cAMP levels, and to determine whether norepinephrine acted directly to increase proliferation of ALL in vitro.

3. Results

3.1. The Nalm-6 acute lymphoblastic leukemia model

To assess the effect of chronic stress on tumor progression in a mouse model of human pre-B cell ALL, we used in vivo bioluminescent imaging to track the colonization of bone marrow and whole body dissemination by luciferase-tagged Nalm-6 cells over a course of 3 weeks following tumor cell inoculation (Fig. 1A). Recapitulating human ALL dynamics, Nalm-6 cells engrafted in femoral bone marrow and other typical ALL target tissues, including lungs, spleen, liver, spinal column, and calvarium. Consistent with progressive hematopoietic failure, examination of femoral bone marrow revealed a reduction in the number of total white blood cells, with flow cytometric analysis indicating that 59 ± 8% of these cells were human Nalm-6 ALL cells rather than normal mouse leukocytes (Fig. 1B).

3.2. Effects of chronic restraint stress

Chronic restraint stress significantly increased Nalm-6 ALL tumor burden in comparison to control mice (mixed effect longitudinal analysis pooling across four independent experiments, average difference 90 ± 38% in whole-body bioluminescence signal, p < .001) (Fig. 2A). Stress had no detectable effect on ALL progression at Day 7, but by Day 14, tumor burden in animals subject to chronic restraint stress increased by an average of 111 ± 28% relative to unstressed controls (p = .003). As presented in Fig. 2B, sub-analyses at this time point showed that chronic restraint stress increased tumor burden in multiple separate body regions, including the hindlimbs (p = .004), thorax (p = .001), mandibular area (p = .046), and calvarium (p = .027). Stress had no significant effect on tumor burden in the upper abdomen (p = .436) and the vertebral column (p = .241). On Day 21, 7 days after the cessation of restraint stress, whole body tumor burden continued to show elevation in stressed animals (average difference: 92 ± 16%, p < .001). Separate body regions continued to show the same pattern of effects on Day 21; hindlimbs (p < .001), thorax (p = .048), mandibular area (p = .034), calvarium (p = .063), upper abdomen (p = .459), vertebral column (p = .484) (data not shown).

3.3. Role of β-adrenergic signaling

To determine whether β-adrenergic receptor activation mediated stress-enhanced ALL growth and dissemination, restraint-stressed mice were treated with the non-selective β-adrenergic antagonist, propranolol, beginning 8 days before initiation of restraint stress and continuing throughout the experimental period. As shown in Fig. 3, there was a significant stress × propranolol interaction effect on total ALL tumor burden (p = .006). Propranolol significantly abrogated stress-enhanced ALL progression by the end of the stress period (average suppression: 97 ± 19%, p = .025). In propranolol-treated mice, stress-exposed animals showed no significant difference in total leukemia growth from control animals (average difference: 3 ± 19%, p = .923). In the absence of stress, propranolol had no significant effect on total Nalm-6 tumor progression compared to placebo (average difference: 44 ± 43%, p = .349). We found no evidence that the effect of propranolol on stress-enhanced tumor burden differed significantly across separate body regions (stress × propranolol × region interaction, p = .427).

3.4. Direct β-adrenergic regulation of Nalm-6 ALL function

To determine whether β-adrenergic signaling might directly regulate Nalm-6 ALL cell biological function, we first examined β-adrenergic receptor expression. RT-PCR analysis showed expression of mRNA encoding β1- and β3-adrenergic receptors in Nalm-6 ALL cells, but minimal expression of mRNA for β2-adrenergic receptors (Fig. 4A). To determine whether Nalm-6 cells responded functionally to β-adrenergic receptor stimulation, we examined intracellular cAMP flux after norepinephrine stimulation in vitro. As presented in Fig. 4B, norepinephrine-stimulated cells showed no significant cAMP signal relative to unstimulated controls (all differences <43 ± 14%, all p > .137). In contrast, forskolin induced significant accumulation of cAMP (all differences >1857 ± 2408%, all p < .001), indicating a robust capacity for cAMP signaling in Nalm-6 ALL cells. To definitively determine whether β-adrenergic
signaling directly affected Nalm-6 ALL cell proliferation, we carried out 4-day longitudinal growth curve assays using physiologically relevant concentrations of norepinephrine (1 and 10 μM). No significant difference in proliferation was detected between norepinephrine-treated cells and vehicle-treated control cultures (condition x time interaction p = .279; Fig. 4C).

4. Discussion

Chronic restraint stress significantly enhanced pre-B ALL tumor burden and dissemination in a well-established mouse xenograft model of the most prevalent form of human pediatric leukemia. Pharmacologic inhibition studies showed that stress effects were
mediated by β-adrenergic signaling in vivo. However, we found no evidence that those in vivo growth and dissemination effects stemmed from direct stimulation of Nalm-6 ALL cell proliferation by β-adrenergic signaling. Thus, the effect of chronic stress on ALL progression in the present model appears to be indirectly mediated by other host cell types that interact with Nalm-6 human ALL cells. Such effects could potentially include SNS regulation of anti-tumor immune responses (Avraham et al., 2006; Ben-Eliyahu et al., 1999; Inbar et al., 2011) and/or SNS regulation of bone marrow stromal cells such as osteoblasts that play a key role in supporting growth and differentiation of healthy hematopoietic cells (Katayama et al., 2006; Mendez-Ferrer et al., 2008). Identification of the specific cellular and molecular mediators of such SNS effects represents an important topic for future research. However, the present data do suggest that pharmacologic antagonism of stress-induced β-adrenergic signaling could represent a novel adjuvant therapeutic strategy for inhibiting such effects.

Mechanistic investigations have documented a key role of β-adrenergic signaling in mediating stress effects on the progression of several types of solid tumor (Sloan et al., 2010; Stefaniski and Ben-Eliyahu, 1996; Thaker et al., 2006). However, the only previous data on the role of the SNS in mediating stress effects on hematopoietic tumors come from a line of research on malignant NK cell proliferation in rats, in which the non-selective β-adrenergic antagonist, nadolol, blocked the effects of an acute swim stress at the time of cancer injection on survival rates (Inbar et al., 2011). That line of research also showed that non-selective β-adrenergic antagonism increased survival rates in the absence of acute swim stress. In contrast, the present study found no effect of β-adrenergic antagonism on ALL progression in the absence of stress. Differences in the specific types of leukemia cells examined and/or the interaction between those cells and the host microenvironment (e.g., bone marrow stromal cells, immune cells, etc.) may account for the differing effects of β-adrenergic inhibition on basal tumor burden growth (i.e., in the absence of stress). Thus, although it will be important to determine if the present in vivo results apply to other ALL subtypes, the results are consistent with a growing body of literature that suggests SNS regulation of tumor biology may represent a relatively general physiologic influence on cancer progression, and, therefore, a broadly applicable target for health protective interventions in the context of human cancer (Antoni et al., 2006).

Findings from the present in vitro studies suggested that β-adrenergic blockade of stress-enhanced ALL progression was not likely due to a direct effect of adrenergic ligands on Nalm-6 ALL cell signaling or proliferation. Such findings are consistent with previous experimental investigations of ovarian cancer (Thaker et al., 2006) and breast cancer (Madden et al., 2011) that showed β-adrenergic signaling influenced cancer cell progression in vivo but did not directly affect cell proliferation in vitro. One potential indirect pathway through which β-adrenergic signaling might regulate Nalm-6 tumor burden involves NK cell-mediated killing of leukemia cells (e.g., as observed for the malignant rat CRNK-16 cell line; Avraham et al., 2006; Inbar et al., 2011). Previous studies indicate that human Nalm-6 ALL and primary ALL samples are generally resistant to human NK cell-mediated killing (Romanski et al., 2005), suggesting that other mechanisms may contribute to the present results. However, it remains possible that murine NK cell responses to human ALL cell lines may have been modulated in the present model system. Future studies could address this issue further by analyzing stress effects on human ALL progression in SCID-Beige mice that lack functional NK cells.
An alternative indirect pathway by which β-adrenergic signaling may affect ALL cell biology involves sympathetic innervation of the stem cell niche in bone marrow. SNS activity regulates both β-adrenergic signaling and definition of the biological interactions by which they support Nalm-6 ALL cell proliferation and dissemination represent important areas for further study.

Previous reports have shown that children and adolescents with ALL manifest high rates of psychological distress as a result of both initial diagnosis and subsequent medical procedures to treat the disease (Kazak et al., 1995; Willingham-Piersol et al., 2008). Adolescent survivors of ALL often manifest higher levels of anxiety in the wake of the disease than their healthy peers (Shelby et al., 1998). Given that the recurrence of ALL remains a significant challenge to medical management of the disease (Nahar and Müschen, 2009), the present results raise the possibility that cancer-related anxiety might contribute to disease recurrence and that pharmacologic inhibition of such effects at the level of the β-adrenergic receptor may represent an effective strategy for managing those effects in patients with pre-B ALL who are in remission or still have active disease.

In summary, the present study demonstrates that chronic stress can enhance the progression of human pre-B cell acute lymphoblastic leukemia in an orthotopic mouse model through an indirect pathway that is regulated by β-adrenergic signaling. These effects suggest novel strategies for protecting ALL patients from the potential biological effects of cancer-related anxiety and other types of stress on leukemia relapse and progression.

**Acknowledgements**

We thank David Stout and Waldemar Ladno at the UCLA Crump Preclinical Imaging Center. Flow cytometry was performed with the assistance of Iris Williams in the UCLA Jonsson Comprehensive Cancer Center (JCCC) and Center for AIDS Research Flow Cytometry Core Facility that is supported by NIH awards CA16042 and AI28697, and by the JCCC, the UCLA AIDS Institute, and the David Geffen School of Medicine at UCLA. This project was also supported in part by NIH Grants T32-MH19925, CA138687, CA116778, and from the UCLA Cousins Center for Psychoneuroimmunology.

**References**


